Drug Combo Improves Recurrence-Free Survival After HCC Resection

The atezolizumab-bevacizumab combination is the first to show efficacy in the adjuvant setting after HCC resection for patients at high risk for recurrence, but the overall survival benefit is unclear.

Related Keywords

Barcelona ,Comunidad Autonoma De Cataluna ,Spain ,Singapore ,Orlando ,Florida ,United States ,American ,Stephenl Chan , ,National Cancer Center Singapore ,Chinese University Of Hong Kong ,American Association For Cancer Research ,American Association ,Cancer Research ,Annual Meeting ,Pierce Chow ,Singapore General Hospital ,Barcelona Clinic Liver Cancer ,Chinese University ,Hong Kong ,Hepatocellular Carcinoma ,Liver Cancer ,Dcc ,Hepatocellular Cancer ,Ancer Liver ,Ancer Hepatocellular ,Biologic Therapy ,Presection ,Antiangiogenesis ,Angiogenesis Inhibitor ,Evacizumab ,Nhibitor Angiogenesis ,Cancer ,Alignant Neoplasia ,Arcinoma ,Humanized Monoclonal Antibody ,Rastuzumab ,Thyroid Disorder ,Tumor ,Adjuvant Setting ,Aminotransferase ,Dust ,Liver Enzymes ,Iver Studie ,